Therefore, the inhibition of the PI3K pathway, particularly the activities of PI3Kα and -δ, may mediate beneficial therapeutic effects in hematological malignancies, including ABL TKI-resistant cells. This evidence concerns the gene PIK3CD and hematologic disorder.